Transforming the treatment paradigm in immunology
Windward Bio is developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases.
Discover Our PipelineAbout Us
Windward Bio is a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases including asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis.
Meet the TeamPipeline
Our pipeline includes 2 clinical-stage programs targeting clinically validated pathways to address respiratory and dermatologic diseases.
See the PipelinePatients
Understanding the patient experience helps inform the development of therapies that address unmet needs in respiratory and dermatologic diseases.
Uncover Gaps in CareOur People
Our team's experience in drug discovery and development, global commercialization, finance, business development, and corporate strategy positions us for success as we build the broader organization needed to bring our therapies to market.
Learn About Open Positions